Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Takeda

Status: Completed

Conditions: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

Treatments: Drug: Brentuximab vedotin (recombinant)

Study type: Observational

Funder types: Industry

Identifiers

NCT02139592

291-011

JapicCTI-142455 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting, as well as to collect efficacy information for reference.

Full description

The present survey was designed to evaluate the safety of brentuximab vedotin (recombinant) for IV infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting.

The usual adult dosage is 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) infused intravenously once every three weeks. The dose should be adjusted depending on the participant's condition. See the "PRECAUTIONS" section of the package insert.

Enrollment: 292 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients treated with brentuximab vedotin IV Infusion

Exclusion criteria

• None

Trial design

292 participants in 1 patient group

brentuximab vedotin (recombinant) Intravenous infusion

Description:

Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks

Treatment:

Drug: Brentuximab vedotin (recombinant)